Weilizhibo announced that LBL-034, a GPRC5D/CD3 bispecific antibody developed independently by the company to treat relapsed/refractory multiple myeloma, gave an oral report at the 67th ASH Annual Meeting. The phase I/II clinical study of LBL-034 was led by Professor Lu Jin of Peking University People's Hospital and conducted at 17 centers across the country. The study confirmed that LBL-034 showed good safety and exciting anti-tumor activity in RRMM patients, showing the best therapeutic potential in its class.

Weilizhibo announced that LBL-034, a GPRC5D/CD3 bispecific antibody developed independently by the company to treat relapsed/refractory multiple myeloma, gave an oral report at the 67th ASH Annual Meeting. The phase I/II clinical study of LBL-034 was led by Professor Lu Jin of Peking University People's Hospital and conducted at 17 centers across the country. The study confirmed that LBL-034 showed good safety and exciting anti-tumor activity in RRMM patients, showing the best therapeutic potential in its class.